This Undervalued Medical-Devices Stock Is Poised for a Rebound
Medtronic offers high growth potential in addition to discounted valuation.
MDT - Medtronic plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$95.80
DETAILS
HIGH:
$119.00
LOW:
$80.00
MEDIAN:
$90.00
CONSENSUS:
$95.80
UPSIDE:
20.75%
Stock News
Worried About a Market Crash? These 3 Dividend Stocks Could Help Reduce Your Risk
These stocks pay between 2.9% and 5.2% in dividends. Their low beta values indicate that they don't follow the market too closely.
Is the Options Market Predicting a Spike in Medtronic Stock?
Investors need to pay close attention to MDT stock based on the movements in the options market lately.
3 Dividend Stocks to Hold for the Long Haul
These three healthcare leaders are slowly overcoming recent obstacles. They have strong dividend track records and the means to maintain healthy dividend growth.
Got $2,500? 1 Unstoppable Medical Juggernaut to Buy Hand Over Fist and Hold for the Next 20 Years
For an investor in their 50s or 60s who is finished chasing trends, Medtronic (NYSE:MDT | MDT Price Prediction) is a stock worth owning for decades because it pairs inelastic demand for medical devices with a 49th consecutive year of dividend increases.
Dividend Announcements: May 30-June 5, 2026
In this article series, I summarize dividend announcements of the past week. Six stocks in my database announced dividend increases, including one stock I own, and one declared a special dividend. W. R. Berkley stands out with an 11.1% dividend increase, a 50¢ special dividend, and the highest quality score this week. Medtronic offers the most value, trading 9% below fair value, but its dividend growth is modest at 1.4%.
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of Scientia Vascular, a privately-held medical device company in Salt Lake City. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.
Medtronic Bets on Ablation, Robotics, and Hypertension
MDT is betting on ablation, robotics and hypertension therapies as next growth drivers, but tariffs, FX and pricing pressures cloud near-term upside.
Is Medtronic Stock a Buy at 14x Forward Earnings?
MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.
5 Best Dividend Stocks to Own in Case the AI Trade Ends
Even the hottest AI stocks won't win forever. Diversification is the key to long-term wealth.
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Tech stocks are pulling back, and healthcare is surging.
Medtronic: A Dividend Aristocrat At A Steal Now
Medtronic plc is a sleepy Dividend Aristocrat with the potential for dividend growth to reaccelerate in the next 12 to 24 months. MDT beat the analyst consensus for revenue and non-GAAP EPS in Q4 2026, with the highest annual revenue growth in 10 years. Medtronic sports an A S&P credit rating with a stable outlook.
Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
Medtronic recently reported strong results, highlighting impressive growth.
Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?
Medtronic's Hugo robotic-assisted surgery platform is approved in the U.S. for urologic procedures, and has more applications pending. Intuitive Surgical's da Vinci is the market's flagship platform, and will be difficult to overtake at this point.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
3 High-Yielding Dividend Stocks That Just Raised Their Payouts
Lowe's, Medtronic, and UnitedHealth Group have been solid dividend growth stocks over the years. They offer above-average payouts and their valuations are also attractive.
Wall Street May Be Mispricing Medtronic, Analyst Says
On Wednesday, Medtronic plc (NYSE:MDT) reported fourth-quarter revenue that exceeded Wall Street expectations, supported by strong growth in its Cardiovascular and Diabetes businesses.
Medtronic Bottoms, Healthy Rebound Ahead
Medtronic's NYSE: MDT primary catalyst as mid-year approaches is that headwinds are not impairing results as much as feared. Rising costs, margin compression, and general uncertainty linked to macroeconomic headwinds were reflected in the company's June 3 earnings results, but the results were inherently strong and expected to remain so.
MDT Q4 Earnings Call Points to Another Year of Growth
MDT touts FY26 as a turning point, keeps FY27 growth targets high, and spotlights CAS and new platforms as investors press on tariffs and TAVR.
Price Targets
Piper Sandler on Medtronic, Inc. (MDT): 'Warming to the Story but Not Quite There'
$85.00
(was $81.14)
Matt O'Brien
·
Piper Sandler
Medtronic price target lowered to $83 from $84 at Goldman Sachs
$83.00
(was $82.28)
David Roman
·
Goldman Sachs
Medtronic price target lowered to $86 from $95 at Truist
$86.00
(was $81.64)
Truist Financial
Medtronic, Inc. (MDT) PT Lowered to $97 at Bernstein SocGen Group
$97.00
(was $82.54)
Lee Hambright
·
Bernstein
Medtronic price target lowered to $85 from $93 at Baird
$85.00
(was $77.95)
David Rescott
·
Robert W. Baird
Medtronic price target lowered to $85 from $90 at UBS
$85.00
(was $77.95)
Priya Sachdeva
·
UBS
Medtronic, Inc. (MDT) PT Lowered to $88 at Jefferies
$88.00
(was $77.95)
Matthew Taylor
·
Jefferies
Medtronic upgraded to Buy at BTIG on consistent organic growth
$90.00
(was $77.95)
BTIG
Medtronic price target lowered to $80 from $95 at Stifel
$80.00
(was $77.95)
Rick Wise
·
Stifel Nicolaus
Medtronic price target lowered to $101 from $120 at Needham
$101.00
(was $78.03)
Mike Matson
·
Needham
Medtronic, Inc. (MDT) PT Lowered to $100 at Mizuho
$100.00
(was $73.75)
Anthony Petrone
·
Mizuho Securities
Medtronic reinstated with a Neutral at Goldman Sachs
$84.00
(was $78.15)
Goldman Sachs
Medtronic price target lowered to $95 from $108 at Jefferies
$95.00
(was $83.79)
Matthew Taylor
·
Jefferies
Medtronic price target lowered to $95 from $103 at Truist
$95.00
(was $86.88)
Richard Newitter
·
Truist Financial
Medtronic price target lowered to $120 from $125 at Mizuho
$120.00
(was $86.75)
Mizuho Securities
Medtronic price target lowered to $106 from $108 at Evercore ISI
$106.00
(was $87.91)
Vijay Kumar
·
Evercore ISI
Leerink Partners Reiterates Outperform Rating on Medtronic, Inc. (MDT): acquisition an "incremental positive"
$119.00
(was $90.31)
Mike Kratky
·
Leerink Partners
Needham Reiterates Buy Rating on Medtronic, Inc. (MDT): "glad to see MDT increasingly pursue tuck-in acquisitions"
$120.00
(was $90.21)
Michael Matson
·
Needham
Medtronic price target lowered to $100 from $103 at Baird
$100.00
(was $96.41)
Robert W. Baird
Medtronic price target raised to $118 from $116 at Barclays
$118.00
(was $96.41)
Matt Miksic
·
Barclays